Accessibility: Skip TopNav
CB-012 allogeneic anti-CLL-1 CAR-T cell therapy
CB-012, a genome-edited allogeneic anti-CLL-1 CAR-T cell therapy with both checkpoint disruption and immune cloaking
Format
PNG
Source
Caribou Biosciences, Inc.
Downloads
Original
Large
Medium
Small